fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Ethinyl estradiol & norethindrone

All products: general benefit

Brevicon · DIN 02187086 · 0.035 mg & 0.5 mg · tablets, 21-pack

General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
Brevicon · DIN 02187086 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2009-02-03 · brand BREVICON 0.5/35 TABLETS (21-DAY PACK) · ATC G03AA05 NORETHISTERONE AND ESTROGEN · form Tablet · route Oral · ingredients ETHINYL ESTRADIOL 0.035 MG, NORETHINDRONE 0.5 MG · company Pfizer canada ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Brevicon: Formulary list price $16.45 per unit (the source does not state the unit; exact figure $16.4500). What the ministry pays, not the patient.

Ministry pays: $16.4500 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02187086)

Source record
DIN 02187086: Brevicon Raw flags: sec3=Y Item: 683200049; group id 798; item number 1946; lccId None; manufacturer id PFI Source form: Tab-21 Pk; strength: 0.035mg & 0.5mg Recorded listing: General benefit Source prices (unrounded): $16.4500; ministry $16.4500 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02187086 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=20162
Shortage status: active shortage (reported March 17, 2026, estimated to end March 19, 2027, last updated May 19, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02187086
Shortage record checked October 6, 2026

Brevicon 1/35 · DIN 02189054 · 0.035 mg & 1 mg · tablets, 21-pack

General benefitMarketed · checked November 18, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
Brevicon 1/35 · DIN 02189054 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2009-02-03 · brand BREVICON 1/35 TABLETS (21-DAY PACK) · ATC G03AA05 NORETHISTERONE AND ESTROGEN · form Tablet · route Oral · ingredients NORETHINDRONE 1 MG, ETHINYL ESTRADIOL 0.035 MG · company Pfizer canada ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Brevicon 1/35: Formulary list price $16.45 per unit (the source does not state the unit; exact figure $16.4500). What the ministry pays, not the patient.

Ministry pays: $16.4500 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02189054)

Source record
DIN 02189054: Brevicon 1/35 Raw flags: sec3=Y Item: 683200053; group id 798; item number 1947; lccId None; manufacturer id PFI Source form: Tab-21 Pk; strength: 0.035mg & 1mg Recorded listing: General benefit Source prices (unrounded): $16.4500; ministry $16.4500 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02189054 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=42921
Shortage status: active shortage (reported June 19, 2026, estimated to end March 19, 2027, last updated October 2, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02189054
Shortage record checked October 6, 2026

Brevicon · DIN 02187094 · 0.035 mg & 0.5 mg · tablets, 28-pack

General benefitMarketed · checked November 18, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
Brevicon · DIN 02187094 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2006-04-18 · brand BREVICON 0.5/35 TABLETS (28-DAY PACK) · ATC G03AA05 NORETHISTERONE AND ESTROGEN · form Tablet · route Oral · ingredients ETHINYL ESTRADIOL .035 MG, NORETHINDRONE .5 MG · company Pfizer canada ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Brevicon: Formulary list price $16.45 per unit (the source does not state the unit; exact figure $16.4500). What the ministry pays, not the patient.

Ministry pays: $16.4500 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02187094)

Source record
DIN 02187094: Brevicon Raw flags: sec3=Y Item: 683200050; group id 798; item number 1949; lccId None; manufacturer id PFI Source form: Tab-28 Pk; strength: 0.035mg & 0.5mg Recorded listing: General benefit Source prices (unrounded): $16.4500; ministry $16.4500 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02187094 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=42888
Shortage status: active shortage (reported June 6, 2025, estimated to end March 19, 2027, last updated May 19, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02187094
Shortage record checked October 6, 2026

Brevicon 1/35 · DIN 02189062 · 0.035 mg & 1 mg · tablets, 28-pack

General benefitMarketed · checked November 18, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
Brevicon 1/35 · DIN 02189062 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2009-02-03 · brand BREVICON 1/35 TABLETS (28-DAY PACK) · ATC G03AA05 NORETHISTERONE AND ESTROGEN · form Tablet · route Oral · ingredients NORETHINDRONE 1 MG, ETHINYL ESTRADIOL 0.035 MG · company Pfizer canada ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Brevicon 1/35: Formulary list price $16.45 per unit (the source does not state the unit; exact figure $16.4500). What the ministry pays, not the patient.

Ministry pays: $16.4500 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02189062)

Source record
DIN 02189062: Brevicon 1/35 Raw flags: sec3=Y Item: 683200054; group id 798; item number 1950; lccId None; manufacturer id PFI Source form: Tab-28 Pk; strength: 0.035mg & 1mg Recorded listing: General benefit Source prices (unrounded): $16.4500; ministry $16.4500 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02189062 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=42922
Shortage status: active shortage (reported January 2, 2026, estimated to end March 19, 2027, last updated May 19, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02189062
Shortage record checked October 6, 2026

Synphasic · DIN 02187116 · 3 Phase · tablets, 28-pack

General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
Synphasic · DIN 02187116 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2006-07-20 · brand SYNPHASIC 28 TABLETS · ATC G03AB04 NORETHISTERONE AND ESTROGEN · form Tablet · route Oral · ingredients NORETHINDRONE 0.5 MG, ETHINYL ESTRADIOL 0.035 MG, NORETHINDRONE 1.0 MG, ETHINYL ESTRADIOL 0.035 MG · company Pfizer canada ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Synphasic: Formulary list price $13.64 per unit (the source does not state the unit; exact figure $13.6400). What the ministry pays, not the patient.

Ministry pays: $13.6400 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02187116)

Source record
DIN 02187116: Synphasic Raw flags: sec3=Y Item: 683200060; group id 798; item number 1951; lccId None; manufacturer id PFI Source form: Tab-28 Pk; strength: 3 Phase Recorded listing: General benefit Source prices (unrounded): $13.6400; ministry $13.6400 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02187116 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=42890
Shortage status: discontinued (September 11, 2026, reported by PFIZER CANADA ULC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02187116
Shortage record checked October 6, 2026

Synphasic · DIN 02187108 · 3 Phase · tablets, 21-pack

General benefit; Health Canada lists this DIN as Cancelled post market since 2026-03-23 — choose a marketed DIN from the same-category list.Discontinued March 23, 2026 · checked November 17, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2026-03-23 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2026-03-23 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
Synphasic · DIN 02187108 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2026-03-23 · brand SYNPHASIC 21 TABLETS · ATC G03AB04 NORETHISTERONE AND ESTROGEN · form Tablet · route Oral · ingredients NORETHINDRONE 0.5 MG, ETHINYL ESTRADIOL 0.035 MG, NORETHINDRONE 1.0 MG, ETHINYL ESTRADIOL 0.035 MG · company Pfizer canada ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Synphasic: Formulary list price $13.64 per unit (the source does not state the unit; exact figure $13.6400). What the ministry pays, not the patient.

Ministry pays: $13.6400 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada); extract: Marketed February 3, 2009; live record preferred: Cancelled Post Market March 23, 2026 (checked November 17, 2026) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02187108)

Source record
DIN 02187108: Synphasic Raw flags: sec3=Y Item: 683200059; group id 798; item number 1948; lccId None; manufacturer id PFI Source form: Tab-21 Pk; strength: 3 Phase Recorded listing: General benefit Source prices (unrounded): $13.6400; ministry $13.6400 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02187108 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada); extract: Marketed February 3, 2009; live record preferred: Cancelled Post Market March 23, 2026 (checked November 17, 2026) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=42889
Shortage status: discontinued (March 23, 2026, reported by PFIZER CANADA ULC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02187108
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since March 23, 2026 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (G03A, G03AA, G03AB): coverage varies; not interchangeable

  • Desogestrel + ethinyl estradiol (Marvelon 21): general benefit
  • Drospirenone + ethinyl estradiol (Yasmin 21): general benefit
  • Ethinyl estradiol + levonorgestrel (Alesse 21): general benefit, not a benefit
  • Ethinyl estradiol + norgestimate (Tri-Cyclen): general benefit, not a benefit
  • Drospirenone (Slynd): general benefit
  • Etonogestrel (Nexplanon): general benefit

3 more in the class list below

Ethinyl estradiol & norethindrone acetate

All products: general benefit

Minestrin 1/20 · DIN 00315966 · 0.02 mg & 1 mg · tablets, 21-pack

General benefit; Health Canada lists this DIN as Cancelled post market since 2022-04-26 — choose a marketed DIN from the same-category list.Discontinued April 26, 2022 · checked November 18, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2022-04-26 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2022-04-26 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
Minestrin 1/20 · DIN 00315966 Manufacturer: Warner Chilcott Canada Co.; listing date 1996-10-01 Health Canada: Cancelled post market since 2022-04-26 · brand MINESTRIN 1/20 · ATC G03AA05 NORETHISTERONE AND ESTROGEN · form Tablet · route Oral · ingredients NORETHINDRONE ACETATE 1 MG, ETHINYL ESTRADIOL 20 MCG · company Allergan inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Minestrin 1/20: Formulary list price $16.99 per unit (the source does not state the unit; exact figure $16.9915). What the ministry pays, not the patient.

Ministry pays: $16.9915 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00315966)

Source record
DIN 00315966: Minestrin 1/20 Raw flags: sec3=Y Item: 683200045; group id 799; item number 1952; lccId None; manufacturer id WAR Source form: Tab-21 Pk; strength: 0.02mg & 1mg Recorded listing: General benefit Source prices (unrounded): $16.9915; ministry $16.9915 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00315966 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2255
Shortage status: resolved shortage (ended February 25, 2021); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00315966
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since April 26, 2022 — choose a marketed DIN from the same-category list.

Minestrin 1/20 · DIN 00343838 · 0.02 mg & 1 mg · tablets, 28-pack

General benefit; Health Canada lists this DIN as Cancelled post market since 2022-04-26 — choose a marketed DIN from the same-category list.Discontinued April 26, 2022 · checked November 17, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2022-04-26 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2022-04-26 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
Minestrin 1/20 · DIN 00343838 Manufacturer: Warner Chilcott Canada Co.; listing date 1996-10-01 Health Canada: Cancelled post market since 2022-04-26 · brand MINESTRIN 1/20 · ATC G03AA05 NORETHISTERONE AND ESTROGEN · form Tablet · route Oral · ingredients NORETHINDRONE ACETATE 1 MG, ETHINYL ESTRADIOL 20 MCG · company Allergan inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Minestrin 1/20: Formulary list price $16.99 per unit (the source does not state the unit; exact figure $16.9915). What the ministry pays, not the patient.

Ministry pays: $16.9915 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00343838)

Source record
DIN 00343838: Minestrin 1/20 Raw flags: sec3=Y Item: 683200046; group id 799; item number 1954; lccId None; manufacturer id WAR Source form: Tab-28 Pk; strength: 0.02mg & 1mg Recorded listing: General benefit Source prices (unrounded): $16.9915; ministry $16.9915 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00343838 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2254
Shortage status: resolved shortage (ended February 5, 2021); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00343838
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since April 26, 2022 — choose a marketed DIN from the same-category list.

Loestrin 1.5/30 · DIN 00297143 · 0.03 mg & 1.5 mg · tablets, 21-pack

General benefit; Health Canada lists this DIN as Cancelled post market since 2022-04-22 — choose a marketed DIN from the same-category list.Discontinued April 22, 2022 · checked November 18, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2022-04-22 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2022-04-22 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
Loestrin 1.5/30 · DIN 00297143 Manufacturer: Warner Chilcott Canada Co.; listing date 1996-10-01 Health Canada: Cancelled post market since 2022-04-22 · brand LOESTRIN 1.5/30 · ATC G03AA05 NORETHISTERONE AND ESTROGEN · form Tablet · route Oral · ingredients NORETHINDRONE ACETATE 1.5 MG, ETHINYL ESTRADIOL 30 MCG · company Allergan inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Loestrin 1.5/30: Formulary list price $16.99 per unit (the source does not state the unit; exact figure $16.9915). What the ministry pays, not the patient.

Ministry pays: $16.9915 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00297143)

Source record
DIN 00297143: Loestrin 1.5/30 Raw flags: sec3=Y Item: 683200006; group id 799; item number 1953; lccId None; manufacturer id WAR Source form: Tab-21 Pk; strength: 0.03mg & 1.5mg Recorded listing: General benefit Source prices (unrounded): $16.9915; ministry $16.9915 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00297143 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1922
Shortage status: resolved shortage (ended January 19, 2021); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00297143
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since April 22, 2022 — choose a marketed DIN from the same-category list.

Loestrin 1.5/30 · DIN 00353027 · 0.03 mg & 1.5 mg · tablets, 28-pack

General benefit; Health Canada lists this DIN as Cancelled post market since 2022-01-20 — choose a marketed DIN from the same-category list.Discontinued January 20, 2022 · checked November 17, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2022-01-20 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2022-01-20 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
Loestrin 1.5/30 · DIN 00353027 Manufacturer: Warner Chilcott Canada Co.; listing date 1996-10-01 Health Canada: Cancelled post market since 2022-01-20 · brand LOESTRIN 1.5/30 · ATC G03AA05 NORETHISTERONE AND ESTROGEN · form Tablet · route Oral · ingredients NORETHINDRONE ACETATE 1.5 MG, ETHINYL ESTRADIOL 30 MCG · company Allergan inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Loestrin 1.5/30: Formulary list price $16.99 per unit (the source does not state the unit; exact figure $16.9915). What the ministry pays, not the patient.

Ministry pays: $16.9915 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00353027)

Source record
DIN 00353027: Loestrin 1.5/30 Raw flags: sec3=Y Item: 683200048; group id 799; item number 1955; lccId None; manufacturer id WAR Source form: Tab-28 Pk; strength: 0.03mg & 1.5mg Recorded listing: General benefit Source prices (unrounded): $16.9915; ministry $16.9915 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00353027 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2386
Shortage status: discontinued (June 25, 2021, reported by ALLERGAN INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00353027
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since January 20, 2022 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (G03A, G03AA, G03AB): coverage varies; not interchangeable

  • Desogestrel + ethinyl estradiol (Marvelon 21): general benefit
  • Drospirenone + ethinyl estradiol (Yasmin 21): general benefit
  • Ethinyl estradiol + levonorgestrel (Alesse 21): general benefit, not a benefit
  • Ethinyl estradiol + norgestimate (Tri-Cyclen): general benefit, not a benefit
  • Drospirenone (Slynd): general benefit
  • Etonogestrel (Nexplanon): general benefit

3 more in the class list below

Norethindrone acetate/ethinyl estradiol & ethinyl estradiol

All strengths: Off-Formulary Interchangeable, not an ODB benefit; same patient cost rules

Shared coverage and patient cost rules
StatusOff-Formulary Interchangeable, not an ODB benefit
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.

Elfy · DIN 02553481 · 1 mg/10 mcg & 10 mcg · tablet-28 tablet Pk

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 17, 2026
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
1 brand, same coverage
Elfy · DIN 02553481 Manufacturer: Apotex Inc.; listing date 2026-06-30 Health Canada: Marketed since 2026-04-20 · brand ELFY · ATC G03AB04 NORETHISTERONE AND ESTROGEN · form Tablet · route Oral · ingredients NORETHINDRONE ACETATE 1 MG, ETHINYL ESTRADIOL 10 MCG, ETHINYL ESTRADIOL 10 MCG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02553481)

Source record
DIN 02553481: Elfy Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 681200006; group id 730; item number 1794; lccId None; manufacturer id APX Source form: Tab-28 Tab Pk; strength: 1mg/10mcg & 10mcg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $16.1084; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02553481 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104242
Interchangeable products
Lolo · DIN 02417456 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02553481
Shortage record checked October 6, 2026

Lolo · DIN 02417456 · 1 mg/10 mcg & 10 mcg · tablet-28 tablet Pk

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 18, 2026
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Savings card: innoviCares lists Lolo (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Lolo · DIN 02417456 Manufacturer: AbbVie Corporation; listing date 2026-06-30 Health Canada: Marketed since 2024-05-06 · brand LOLO · ATC G03AB04 NORETHISTERONE AND ESTROGEN · form Tablet · route Oral · ingredients NORETHINDRONE ACETATE 1 MG, ETHINYL ESTRADIOL 10 MCG, ETHINYL ESTRADIOL 10 MCG · company Abbvie corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Lolo: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02417456)

Source record
DIN 02417456: Lolo Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 681200006; group id 730; item number 1794; lccId None; manufacturer id ABV Source form: Tab-28 Tab Pk; strength: 1mg/10mcg & 10mcg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02417456 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90215
Interchangeable products
Elfy · DIN 02553481 · not recorded
Shortage status: resolved shortage (ended September 5, 2019); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02417456
Shortage record checked October 6, 2026

Other products in the same Health Canada class (G03A, G03AA, G03AB): coverage varies; not interchangeable

  • Desogestrel + ethinyl estradiol (Marvelon 21): general benefit
  • Drospirenone + ethinyl estradiol (Yasmin 21): general benefit
  • Ethinyl estradiol + levonorgestrel (Alesse 21): general benefit, not a benefit
  • Ethinyl estradiol + norgestimate (Tri-Cyclen): general benefit, not a benefit
  • Drospirenone (Slynd): general benefit
  • Etonogestrel (Nexplanon): general benefit

3 more in the class list below

Other drugs in the same formulary classes and how they are covered

Other drugs in the same formulary class (68:12 Contraceptives) and how they are covered

Matched class: 68:12 Contraceptives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ETONOGESTREL, LEVONORGESTREL 68:12 Contraceptives

ETONOGESTREL

· 1 products · General benefit · strengths: 68mg/Implant · ER Subdermal Implant

LEVONORGESTREL

· 2 products · General benefit · strengths: 19.5mg, 52mg · Insert

ETHINYL ESTRADIOL & ETONOGESTREL

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.120mg & 0.015mg/24 hr · Slow Release Vag Ring Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 68:12
Full class listing Related classes: 68:04 Corticosteroids, 68:08 Androgens, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:32 Progestogens and Oral Contraceptives, 68:36 Thyroids, 68:38 Anti-Thyroids

Other drugs in the same formulary class (68:32 Progestogens and Oral Contraceptives) and how they are covered

Matched class: 68:32 Progestogens and Oral Contraceptives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DESOGESTREL & ETHINYL ESTRADIOL, DROSPIRENONE, DROSPIRENONE & ETHINYL ESTRADIOL, LEVONORGESTREL Some products covered without a code (check the product listing): ETHINYL ESTRADIOL & LEVONORGESTREL, MEDROXYPROGESTERONE ACETATE, NORETHINDRONE, NORGESTIMATE & ETHINYL ESTRADIOL 68:32 Progestogens and Oral Contraceptives

DESOGESTREL & ETHINYL ESTRADIOL

· 12 products · General benefit · strengths: 0.15mg & 0.03mg, 3 Phase · Tab-21 Pk, Tab-28 Pk, Tabs-21 Pk, Tabs-28 Pk

DROSPIRENONE & ETHINYL ESTRADIOL

· 9 products · General benefit · strengths: 3.0mg & 0.03mg, 3.0mg & 0.02mg · Tab-21 Pk, Tab-28 Pk

ETHINYL ESTRADIOL & LEVONORGESTREL

· 20 products · General benefit (18), Off-Formulary Interchangeable, not an ODB benefit (2) · strengths: 20mcg & 100mcg, 0.03mg & 0.15mg, 3 Phase · Tab-21 Pk, Tab-28 Pk, Tab-91 Pk

NORGESTIMATE & ETHINYL ESTRADIOL

· 10 products · Listed, not a benefit (4), General benefit (6) · strengths: 3 Phase · Tab-21 Pk, Tab-28 Pk

DROSPIRENONE

· 1 products · General benefit · strengths: 4mg · Tab-28 Tab Pk

LEVONORGESTREL

· 4 products · General benefit · strengths: 1.5mg · Tab-1 Tab Pk

MEDROXYPROGESTERONE ACETATE

· 10 products · Temporary benefit (2), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (3), General benefit (4), Listed, not a benefit (1) · strengths: 150mg/mL, 2.5mg, 5mg, 10mg, 100mg · Inj Sol-1mL Pref Syr, Tab

NORETHINDRONE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 0.35mg · Tab-28 Pk

DIENOGEST

· 5 products · Limited Use, codes 432 · strengths: 2mg · Tab

CYPROTERONE ACETATE & ETHINYL ESTRADIOL

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2mg & 0.035mg · Tab-21 Pk

PROGESTERONE

· 8 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 68:32
Full class listing Related classes: 68:04 Corticosteroids, 68:08 Androgens, 68:12 Contraceptives, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications BREVICON 0.5/35 and BREVICON 1/35 (norethindrone and ethinyl estradiol) are indicated for: • the prevention of pregnancy. 1.1. Pediatrics The safety and efficacy of BREVICON has been established in women of reproductive age. Use of these products before menarche is not indicated. 1.2. Geriatrics BREVICON is not indicated for use in postmenopausal women. https://pdf.hres.ca/dpd_pm/00081309.PDF PM date: 2025-08-07 Source product: BREVICON 0.5/35 TABLETS (21-DAY PACK); DIN 02187086; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
Product monograph unavailable: no marketed product found
What the Health Canada label says it is for
1 INDICATIONS LOLO® (ethinyl estradiol / norethindrone acetate and ethinyl estradiol) is indicated for: • the prevention of pregnancy. In a one year (thirteen 28-day cycles) multicenter open-label clinical trial 1,582 women were studied to assess the safety and efficacy of LOLO. In this study 1,270 women 18 to 35 years of age were studied to assess the efficacy of LOLO, completing the equivalent of 12,482 28-day evaluable cycles of exposure. The pregnancy rate (Pearl Index [PI]) in women 18 to 35 years of age was 2.92 pregnancies per 100 women-years of use. See 14 CLINICAL TRIALS. The efficacy of LOLO in women with a body mass index > 35 kg/m2 has not been evaluated. Exposure to exogenous estrogen with LOLO is less than with other combined oral contraceptives with similar synthetic estrogens. Any benefits from the lower estrogen exposure provided by LOLO have not been evaluated. 1.1 Pediatrics Pediatrics (< 18 years): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics: No data are available to Health Canada; therefore, Health Canada has not authorized an indication for… https://pdf.hres.ca/dpd_pm/00077458.PDF PM date: DEC 12, 2013 Source product: LOLO; DIN 02417456; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Brevicon · DIN 02187086 Shortage status: active shortage (reported 2026-03-17, estimated to end 2027-03-19, last updated 2026-05-19); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02187086

Check this DIN again

Brevicon 1/35 · DIN 02189054 Shortage status: active shortage (reported 2026-06-19, estimated to end 2027-03-19, last updated 2026-10-02); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02189054

Check this DIN again

Brevicon · DIN 02187094 Shortage status: active shortage (reported 2025-06-06, estimated to end 2027-03-19, last updated 2026-05-19); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02187094

Check this DIN again

Brevicon 1/35 · DIN 02189062 Shortage status: active shortage (reported 2026-01-02, estimated to end 2027-03-19, last updated 2026-05-19); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02189062

Check this DIN again

Synphasic · DIN 02187116 Shortage status: discontinued (2026-09-11, reported by PFIZER CANADA ULC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02187116

Check this DIN again

Synphasic · DIN 02187108 Shortage status: discontinued (2026-03-23, reported by PFIZER CANADA ULC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02187108

Check this DIN again

Loestrin 1.5/30 · DIN 00353027 Shortage status: discontinued (2021-06-25, reported by ALLERGAN INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00353027

Check this DIN again

Other review policies

For Elfy, Lolo: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026